Invitae CEO says the diagnostic company has big plans for genomic medicine
“We’re building a company for the coming genomic era that includes genetic capabilities through all phases of life,” said Invitae CEO Sean George in a phone interview.
Carrier screening through Amazon? Good Start Genetics expands its online presence
Selling physician-ordered carrier screening kits on Amazon may not seem like a logical fit, but there are a number of benefits that Good Start Genetics is now tapping into.
With the Rise of AI, What IP Disputes in Healthcare Are Likely to Emerge?
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
The Versatility of Genetic Testing: Cystic Fibrosis
Genetic testing can play a critical role in helping potential parents understand their options if they are carriers for a wide array of genetic disorders, such as cystic fibrosis.
Cambridge firm uses next-generation DNA sequencing to detect more mutations in carrier screening
When a company sets out to enter a market inhabited by heavyweights like LabCorp and Quest Diagnostics, it better have something good. Good Start Genetics has applied next-generation DNA sequencing to existing knowledge and testing methods to come up with what it thinks is that something special. The company has developed a series of […]
Good Start Genetics repays Massachusetts accelerator loan
Good Start Genetics Inc., which earlier this month raised $18 million in venture financing, has repaid its debt to the Commonwealth in full, or at least until next tax season. The Boston-based company, which is developing a pre-pregnancy genetic test designed to screen for a panel of genetic disorders, won a $500,000 "accelerator" loan from the Massachusetts Life Sciences Center in April 2009. It's the first of the seven companies to receive the state's assistance to pay off its loan.
Good Start Genetics raises $18M for pre-pregnancy genetic test
Good Start Genetics Inc. closed an $18 million Series A funding round, and tapped former Exact Sciences Corp. (NSDQ: EXAS) head Don Hardison to be its president and CEO. The Boston-based company is developing a pre-pregnancy genetic test designed to screen for a panel of genetic disorders, including sickle-cell anemia and cystic fibrosis.
A Deep-dive Into Specialty Pharma
A specialty drug is a class of prescription medications used to treat complex, chronic or rare medical conditions. Although this classification was originally intended to define the treatment of rare, also termed “orphan” diseases, affecting fewer than 200,000 people in the US, more recently, specialty drugs have emerged as the cornerstone of treatment for chronic and complex diseases such as cancer, autoimmune conditions, diabetes, hepatitis C, and HIV/AIDS.